A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
Overview of attention for article published in Annals of Oncology, July 2013
Altmetric Badge
About this Attention Score
-
Average Attention Score compared to outputs of the same age
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 81 Mendeley